BOOKS BY CATEGORY
Your Account
Clinical Handbook of Psychotropic Drugs: 2019
Price
Quantity
£64.00
(To see other currencies, click on price)
Spiral bound
Add to basket  

MORE ABOUT THIS BOOK

Main description:

The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. * Independent, unbiased, up-to-date - now with esketamine (Spravato) * Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options * Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine * New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar * Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug * Potential interactions and side effects summarized in comparison charts * With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek * Clearly written patient information sheets available for download as printable PDF files This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs. ------------------------------------------------------------------------------------------- New in this edition: * Antidepressants chapter includes new section on esketamine (Spravato), recently approved for treatment-resistant depression; also updates to antidepressant use in pregnancy and SPARI drug interactions * Antipsychotics updates include new section on 5-HT2A inverse agonist antipsychotic (pimavanserin, Nuplazid) and comprehensive revision of augmentation strategies * Pharmacogenomics chapter fully revised with expanded dose adjustment recommendations * Chart of agents under investigation for treatment of substance use disorders fully revised, new agents include lofexidine (Lucemyra), Kadian, nortriptyline e-cigarettes * Unapproved treatments chapter with significant updates, including new sections on adrenergic agents in PTSD (doxazosin), antiflammatory agents in depression (pioglitazone, rosiglitazone, statins), and hormones in schizophrenia (raloxifene) * Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine * New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar


Contents:

Antidepressants Selective Serotonin Reuptake Inhibitors (SSRI) * Norepinephrine Dopamine Reuptake Inhibitor (NDRI) * Serotonin Norepinephrine Reuptake Inhibitor (SNRI) * Serotonin-2 Antagonists / Reuptake Inhibitors (SARI) * Serotonin-1A Agonist/Serotonin Reuptake Inhibitor (SPARI) * Serotonin Modulator and Stimulator (SMS) * Noradrenergic / Specific Serotonergic Antidepressants (NaSSA) * Nonselective Cyclic Antidepressants * Monoamine Oxidase Inhibitors * Reversible Inhibitor of MAO-A (RIMA) * Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs) * Irreversible MAO-B Inhibitor * Effects of Antidepressants on Neurotransmitters / Receptors * Pharmacological Effects of Antidepressants on Neurotransmitters / Receptors * Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses * Antidepressant Doses and Pharmacokinetics * Switching Antidepressants * Antidepressant Augmentation Strategies Electroconvulsive Therapy (ECT) Bright Light Therapy (BLT) Repetitive Transcranial Magnetic Stimulation (rTMS) Antipsychotics Second-Generation Antipsychotics / SGAs * Third-Generation Antipsychotic / TGA * 5-HT21 Inverse Agonist Antipsychotic * First- Generation Antipsychotics / FGAs * Effects of Antipsychotics on Neurotransmitters / Receptors * Pharmacological Effects of Antipsychotics on Neurotransmitters / Receptor Subtypes * Relative Tolerability Profiles of Anti-psychotics * Frequency of Adverse Reactions to Antipsychotics at Therapeutic Doses * Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections) * Comparison of Long-Acting IM Antipsychotics * Switching Antipsychotics * Antipsychotic Augmentation Strategies Antipsychotic-Induced Extrapyramidal Side Effects and Their Management Extrapyramidal Adverse Effects of Antipsychotics * Treatment Options for Extrapyramidal Side Effects * Effects on Extrapyramidal Symptoms * Comparison of Agents for Treating Acute Extrapyramidal Side Effects * Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects Anxiolytic (Antianxiety) Agents Benzodiazepines * Comparison of the Benzodiazepines * Buspirone Hypnotics / Sedatives L-Tryptophan * Comparison of Hypnotics / Sedatives Mood Stabilizers Lithium * Anticonvulsants * Comparison of Anticonvulsants * Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses Drugs for ADHD Psychostimulants * Atomoxetine * Comparison of Drugs for ADHD * 2 Agonists * Augmentation Strategies in ADHD Drugs for Treatment of Dementia Cholinesterase Inhibitors * Memantine * Comparison of Drugs for Treatment of Dementia Sex-Drive Depressants Comparison of Sex-Drive Depressants Drugs of Abuse Alcohol * Stimulants * Hallucinogens * Opioids * Inhalants / Aerosols * Gamma-hydroxybutyrate (GHB) / Sodium Oxybate * Flunitrazepam (Rohypnol) * Nicotine / Tobacco Treatment of Substance Use Disorders Acamprosate * Disulfiram * Naltrexone * Buprenorphine * Methadone * Pharmacotherapy for Nicotine / Tobacco Use Disorder * Comparison of Treatments for Nicotine / Tobacco Use Disorder Unapproved Treatments of Psychiatric Disorders Adrenergic Agents * Anti-Inflammatory Agents * Dopaminergic Agents * GABA Agents / Anticonvulsants * Hormones * NMDA Agents * 5-HT3 Antagonists * Miscellaneous Natural Health Products Pharmacogenomic Information for Common Psychotropic Drugs Glossary Drug Use in Pregnancy and Effects on Breast Milk Patient Information Sheets Appendix: Neuroscience-Based Nomenclature Index of Drugs


PRODUCT DETAILS

ISBN-13: 9780889375611
Publisher: Hogrefe Publishing
Publication date: May, 2019
Pages: 454
Weight: 571g
Availability: Available
Subcategories: Pharmacology, Psychiatry

MEET THE AUTHOR

Ric M. Procyshyn; BScPharm, MSc, PharmD, PhD; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada. Kalyna Z. Bezchlibnyk-Butler; BScPharm, FCSHP; Toronto, ON, Canada. J. Joel Jeffries; MB, FRCPC, DFCPA; Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, ON, Canada

CUSTOMER REVIEWS

Average Rating 

Previous praise for the Clinical Handbook: As a psychiatrist who routinely prescribes medications, I find this handbook invaluable. It is the most comprehensive book on this topic that I have come across.; Corey Goldstein, MD, Rush University Medical Center; A powerhouse of practical information ...Unrivalled in scope ... This outstanding and unique handbook is as rich in useful content as many full textbooks.; Barbara Jovaisas, PharmD, in Canadian Pharmacists Journal.; Comprehensive ... clearly organized ... an ideal resource for rapid and straight-forward retrieval of essential clinical information ...a `must have' for those who work in mental health care.; Marshall Cates, PharmD, in Annals of Pharmacotherapy.; Should be available at all nursing stations.; C. Lindsay DeVane, PharmD, in American Journal of Health Systems Pharmacy.; The handbook is easy to use, comprehensive in scope, and up to date - a winner!; Catherine Chiles, MD, in the Journal of Clinical Psychiatry